Lantern Pharma (LTRN) Retained Earnings (2019 - 2026)

Lantern Pharma (LTRN) has reported Retained Earnings for 8 consecutive years, with -$103.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings fell 206.35% year-over-year to -$103.5 million; the trailing twelve-month figure through Jun 2026 stood at -$103.5 million (down 206.35% YoY), and the FY2025 full-year result was $99.7 million, up 2.67% from the prior year.
• Retained Earnings declined to -$103.5 million in Q2 2026 per LTRN's latest filing, from $100.0 million in the prior quarter.
• Across five years, Retained Earnings topped out at $100.0 million in Q1 2026 and bottomed at -$103.5 million in Q2 2026.
• Historically, Retained Earnings has averaged $85.7 million across 5 years, with a median of $96.5 million in 2024.
• The widest YoY moves for Retained Earnings: up 2.83% in 2026, down 206.35% in 2026.
• Over 5 years, Retained Earnings stood at $95.7 million in 2022, then advanced by 0.59% to $96.3 million in 2023, then rose by 0.83% to $97.1 million in 2024, then increased by 2.67% to $99.7 million in 2025, then sank by 203.91% to -$103.5 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$103.5 million, $100.0 million, and $99.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.